Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thrombosis Risk In Taxus And Cypher Is Real, TCT Data Shows; Now What?

This article was originally published in The Gray Sheet

Executive Summary

With a growing consensus coming out of last week's Transcatheter Cardiovascular Therapeutics meeting that first-generation drug-eluting stents (DES) are associated with an increased long-term risk of blood clots, cardiologists are grappling with how use of these blockbuster products might need to be modified

You may also be interested in...



Newer Drug-Eluting Stents May Leave Late Thrombosis Saga Behind – Meta-Analysis

In an analysis of about 50,000 patients in 49 different clinical studies, cobalt-chromium everolimus-eluting stents like Abbott’s Xience showed a definitive thrombosis advantage over bare-metal stents at one year and two years following the initial procedure.

Newer Drug-Eluting Stents May Put Late Thrombosis Issues To Rest – Meta-Analysis

In an analysis of about 50,000 patients in 49 different clinical studies, cobalt-chromium everolimus-eluting stents like Abbott’s Xience showed a definitive thrombosis advantage over bare-metal stents at one year and two years following the initial procedure.

NEJM Articles Fuel Debate On Drug-Eluting-Stent Safety

Results of a Swedish registry of almost 20,000 patients, published in the New England Journal of Medicine, are adding fuel to the ongoing debate on drug-eluting-stent safety

Related Content

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel